Urinary Prostaglandin as a Potential Predictive Marker for Thiazide-induced Hyponatremia

Launched by UNIVERSITY HOSPITAL, BASEL, SWITZERLAND · Sep 12, 2022

Keywords

ClinConnect Summary

This clinical trial is studying whether the level of a substance called urinary prostaglandin E2 (PGE2) in the urine can help predict if patients will develop a condition known as thiazide-induced hyponatremia (TIH) after starting treatment with thiazide diuretics, which are commonly used to lower blood pressure. Researchers want to see if measuring this substance before starting the medication can give an early warning about the risk of TIH within the first four weeks of treatment.

To participate in this study, individuals must be at least 18 years old and newly prescribed a thiazide or thiazide-like diuretic. However, those who have taken these medications in the past month, already have low sodium levels, or have certain medical conditions or treatments will not be eligible. Participants can expect to provide urine samples and undergo regular check-ups to monitor their health during the study. This research aims to improve how we manage patients on these medications, ensuring safer and more effective treatment.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Newly prescribed thiazide or thiazide-like diuretic
• • ≥ 18 years of age
• • Informed Consent as documented by signature
• Exclusion Criteria:
• • Intake of thiazide or thiazide-like diuretic in the preceding month
• • Hyponatremia (plasma sodium \<135 mmol/L) at baseline
• • Acute infectious / inflammatory disease (CRP ≥ 20 mg/L \[1, 11\])
• • Symptomatic urinary tract infection
• • Chronic treatment with NSAID and / or NSAID intake 48 hours prior to urine sampling at visit 1 and 2 (intake of acetylsalicylic acid will be no exclusion criteria)
• • End of life care, no informed consent or inability to follow the procedures of the study, e.g., due to language barriers, psychological disorders, dementia